Morales-Martinez Mario, Valencia-Hipolito Alberto, Vega Gabriel G, Neri Natividad, Nambo Maria J, Alvarado Isabel, Cuadra Ivonne, Duran-Padilla Marco A, Martinez-Maza Otoniel, Huerta-Yepez Sara, Vega Mario I
Molecular Signal Pathway in Cancer Laboratory, UIMEO, Oncology Hospital, Siglo XXI National Medical Center, IMSS, México City, México.
Unidad de Posgrado, Facultad de Medicina Universidad Nacional Autónoma de México, México City, México.
Oncotarget. 2019 Mar 15;10(22):2173-2188. doi: 10.18632/oncotarget.26745.
Krüppel-Like Factor 4 (KLF4) is a member of the KLF transcription factor family, and evidence suggests that KLF4 is either an oncogene or a tumor suppressor. The regulatory mechanism underlying KLF4 expression in cancer, and specifically in lymphoma, is still not understood. Bioinformatics analysis revealed two YY1 putative binding sites in the KLF4 promoter region (-950 bp and -105 bp). Here, the potential regulation of KLF4 by YY1 in NHL was analyzed. Mutation of the putative YY1 binding sites in a previously reported system containing the KLF4 promoter region and CHIP analysis confirmed that these binding sites are important for KLF4 regulation. B-NHL cell lines showed that both KLF4 and YY1 are co-expressed, and transfection with siRNA-YY1 resulted in significant inhibition of KLF4. The clinical implications of YY1 in the transcriptional regulation of KLF4 were investigated by IHC in a TMA with 43 samples of subtypes DLBCL and FL, and all tumor tissues expressing YY1 demonstrated a correlation with KLF4 expression, which was consistent with bioinformatics analyses in several databases. Our findings demonstrated that KLF4 can be transcriptionally regulated by YY1 in B-NHL, and a correlation between YY1 expression and KLF4 was found in clinical samples. Hence, both YY1 and KLF4 may be possible therapeutic biomarkers of NHL.
Krüppel样因子4(KLF4)是KLF转录因子家族的成员,有证据表明KLF4既是一种癌基因,也是一种肿瘤抑制因子。KLF4在癌症特别是淋巴瘤中的表达调控机制仍不清楚。生物信息学分析揭示了KLF4启动子区域(-950 bp和-105 bp)中的两个YY1假定结合位点。在此,分析了YY1在非霍奇金淋巴瘤(NHL)中对KLF4的潜在调控作用。在先前报道的包含KLF4启动子区域的系统中对假定的YY1结合位点进行突变,并通过染色质免疫沉淀(CHIP)分析证实这些结合位点对KLF4的调控很重要。B-NHL细胞系显示KLF4和YY1共表达,用siRNA-YY1转染导致KLF4受到显著抑制。通过免疫组化(IHC)在一个包含43个弥漫性大B细胞淋巴瘤(DLBCL)和滤泡性淋巴瘤(FL)亚型样本的组织芯片(TMA)中研究了YY1在KLF4转录调控中的临床意义,所有表达YY1的肿瘤组织都显示出与KLF4表达相关,这与几个数据库中的生物信息学分析结果一致。我们的研究结果表明,在B-NHL中KLF4可受YY1转录调控,并且在临床样本中发现了YY1表达与KLF4之间的相关性。因此,YY1和KLF4都可能是非霍奇金淋巴瘤的潜在治疗生物标志物。